Evidence map›Paper›PMID 40281586›Full record

ArticleMolecular neurodegeneration2025

Spectrum of γ-Secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes.

Sara Gutiérrez Fernández, Cristina Gan Oria, Dieter Petit, Wim Annaert, John M Ringman, Nick C Fox, Natalie S Ryan, Lucía Chávez-Gutiérrez

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Correlations ofAlzheimer's & dementia (New York, N. Y.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara Gutiérrez FernándezVIB-KU Leuven Center for Brain & Disease Research, Herestraat 49 Box 602, Louvain, 3000, Belgium.
Cristina Gan OriaVIB-KU Leuven Center for Brain & Disease Research, Herestraat 49 Box 602, Louvain, 3000, Belgium.
Dieter PetitVIB-KU Leuven Center for Brain & Disease Research, Herestraat 49 Box 602, Louvain, 3000, Belgium.
Wim AnnaertVIB-KU Leuven Center for Brain & Disease Research, Herestraat 49 Box 602, Louvain, 3000, Belgium.
John M RingmanDepartment of Neurology, Alzheimer's Disease Research Center, Center for Health Professions, University of Southern California, 1520 Alcazar Street, Suite 210, Los Angeles, CA, 90033, USA.
Nick C FoxDementia Research Institute at UCL, Queen Square, London, WC1 N 3BG, UK.
Natalie S RyanDementia Research Institute at UCL, Queen Square, London, WC1 N 3BG, UK.
Lucía Chávez-GutiérrezVIB-KU Leuven Center for Brain & Disease Research, Herestraat 49 Box 602, Louvain, 3000, Belgium. Lucia.ChavezGutierrez@kuleuven.be.

Funding

Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
Fonds Wetenschappelijk Onderzoek G008023NFonds Wetenschappelijk Onderzoek G0C4220NFonds Wetenschappelijk Onderzoek SB 1S59621NNIA NIH HHS P01 AG052350NIA NIH HHS P30 AG066530Stichting Alzheimer Onderzoek, BE 2021/0012Stichting Alzheimer Onderzoek, BE 2022/022UK Dementia Research InstituteUK NIHR UCLH Biomedical Research Centre
6 · The paper itself

Abstract

backgroundAutosomal Dominant Alzheimer's Disease (ADAD), caused by mutations in Presenilins (PSEN1/2) and Amyloid Precursor Protein (APP) genes, typically manifests with early onset (< 65 years). Age at symptom onset (AAO) is relatively consistent among carriers of the same PSEN1 mutation, but more variable for PSEN2 and APP variants, with these mutations associated with later AAOs than PSEN1. Understanding this clinical variability is crucial for understanding disease mechanisms, developing predictive models and tailored interventions in ADAD, with potential implications for sporadic AD.

methodsWe performed biochemical assessment of γ-secretase dysfunction on 28 PSEN2 and 19 APP mutations, including disease-associated, unclear and benign variants. This analysis has been valuable in the assessment of PSEN1 variant pathogenicity, disease onset and progression.

resultsOur analysis reveals linear correlations between the molecular composition of Aβ profiles and AAO for both PSEN2 (R

conclusionThis study supports a unified model of ADAD pathogenesis wherein γ-secretase dysfunction and the resulting shifts in Aβ profiles are central to disease onset across all causal genes. While similar shifts in Aβ occur across causal genes, their impact on AAO varies in the function of their contribution to APP processing in the brain. This biochemical analysis establishes quantitative relationships that enable predictive AAO modelling with implications for clinical practice and genetic research. Our findings also support the development of therapeutic strategies modulating γ-secretase across different genetic ADAD forms and potentially more broadly in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesPresenilin-1Presenilin-2AgedAge of OnsetFemaleHumansMaleMembrane ProteinsMiddle AgedMutationAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAPP protein, humanMembrane ProteinsPresenilin-1Presenilin-2PSEN1 protein, humanPSEN2 protein, humanPSENEN protein, humanAge at dementia onset and Familial Alzheimer’s diseaseAmyloid-βAPPAutosomal dominant Alzheimer’s diseasePresenilin

Identifiers

PMID40281586
PMCPMC12032737

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.